Nicholas J White1, Tran T Duong1, Chirapong Uthaisin1, François Nosten1, Aung P Phyo1, Borimas Hanboonkunupakarn1, Sasithon Pukrittayakamee1, Podjanee Jittamala1, Kittiphum Chuthasmit1, Ming S Cheung1, Yiyan Feng1, Ruobing Li1, Baldur Magnusson1, Marc Sultan1, Daniela Wieser1, Xiaolei Xun1, Rong Zhao1, Thierry T Diagana1, Peter Pertel1, F Joel Leong1. 1. From the Mahidol-Oxford Tropical Medicine Research Unit (MORU) (N.J.W.) and the Department of Clinical Tropical Medicine (B.H., S.P., P.J.), Faculty of Tropical Medicine, Mahidol University, Bangkok, Shoklo Malaria Research Unit (SMRU), Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (F.N., A.P.P.), Phusing Hospital, 83/1 Tambon Huay Tikchu, Phusing District, Srisaket (K.C.), and Mae Ramat District Hospital, Mae Ramat District, Tak (C.U.) - all in Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom (N.J.W., F.N.); National Institute for Malariology, Parasitology and Entomology, Tu Liem District, Hanoi (D.T.T.); Novartis Institutes for BioMedical Research (M.S.C., M.S., D.W.) and Novartis Pharma (B.M.) - both in Basel, Switzerland; Novartis Institutes for BioMedical Research (Y.F., R.Z.) and Novartis Pharma (China) (X.X.), Shanghai, and Novartis Institutes for BioMedical Research, Beijing (R.L.) - all in China; Novartis Institute for Tropical Diseases, Singapore (T.T.D., F.J.L.); and Novartis Institutes for BioMedical Research, Cambridge, MA (P.P.).
Abstract
BACKGROUND: KAF156 belongs to a new class of antimalarial agents (imidazolopiperazines), with activity against asexual and sexual blood stages and the preerythrocytic liver stages of malarial parasites. METHODS: We conducted a phase 2, open-label, two-part study at five centers in Thailand and Vietnam to assess the antimalarial efficacy, safety, and pharmacokinetic profile of KAF156 in adults with acute Plasmodium vivax or P. falciparum malaria. Assessment of parasite clearance rates in cohorts of patients with vivax or falciparum malaria who were treated with multiple doses (400 mg once daily for 3 days) was followed by assessment of the cure rate at 28 days in a separate cohort of patients with falciparum malaria who received a single dose (800 mg). RESULTS: Median parasite clearance times were 45 hours (interquartile range, 42 to 48) in 10 patients with falciparum malaria and 24 hours (interquartile range, 20 to 30) in 10 patients with vivax malaria after treatment with the multiple-dose regimen and 49 hours (interquartile range, 42 to 54) in 21 patients with falciparum malaria after treatment with the single dose. Among the 21 patients who received the single dose and were followed for 28 days, 1 had reinfection and 7 had recrudescent infections (cure rate, 67%; 95% credible interval, 46 to 84). The mean (±SD) KAF156 terminal elimination half-life was 44.1±8.9 hours. There were no serious adverse events in this small study. The most common adverse events included sinus bradycardia, thrombocytopenia, hypokalemia, anemia, and hyperbilirubinemia. Vomiting of grade 2 or higher occurred in 2 patients, 1 of whom discontinued treatment because of repeated vomiting after receiving the single 800-mg dose. More adverse events were reported in the single-dose cohort, which had longer follow-up, than in the multiple-dose cohorts. CONCLUSIONS: KAF156 showed antimalarial activity without evident safety concerns in a small number of adults with uncomplicated P. vivax or P. falciparum malaria. (Funded by Novartis and others; ClinicalTrials.gov number, NCT01753323 .).
BACKGROUND:KAF156 belongs to a new class of antimalarial agents (imidazolopiperazines), with activity against asexual and sexual blood stages and the preerythrocytic liver stages of malarial parasites. METHODS: We conducted a phase 2, open-label, two-part study at five centers in Thailand and Vietnam to assess the antimalarial efficacy, safety, and pharmacokinetic profile of KAF156 in adults with acute Plasmodium vivax or P. falciparum malaria. Assessment of parasite clearance rates in cohorts of patients with vivax or falciparum malaria who were treated with multiple doses (400 mg once daily for 3 days) was followed by assessment of the cure rate at 28 days in a separate cohort of patients with falciparum malaria who received a single dose (800 mg). RESULTS: Median parasite clearance times were 45 hours (interquartile range, 42 to 48) in 10 patients with falciparum malaria and 24 hours (interquartile range, 20 to 30) in 10 patients with vivax malaria after treatment with the multiple-dose regimen and 49 hours (interquartile range, 42 to 54) in 21 patients with falciparum malaria after treatment with the single dose. Among the 21 patients who received the single dose and were followed for 28 days, 1 had reinfection and 7 had recrudescent infections (cure rate, 67%; 95% credible interval, 46 to 84). The mean (±SD) KAF156 terminal elimination half-life was 44.1±8.9 hours. There were no serious adverse events in this small study. The most common adverse events included sinus bradycardia, thrombocytopenia, hypokalemia, anemia, and hyperbilirubinemia. Vomiting of grade 2 or higher occurred in 2 patients, 1 of whom discontinued treatment because of repeated vomiting after receiving the single 800-mg dose. More adverse events were reported in the single-dose cohort, which had longer follow-up, than in the multiple-dose cohorts. CONCLUSIONS:KAF156 showed antimalarial activity without evident safety concerns in a small number of adults with uncomplicated P. vivax or P. falciparum malaria. (Funded by Novartis and others; ClinicalTrials.gov number, NCT01753323 .).
Authors: Kyaw M Tun; Mallika Imwong; Khin M Lwin; Aye A Win; Tin M Hlaing; Thaung Hlaing; Khin Lin; Myat P Kyaw; Katherine Plewes; M Abul Faiz; Mehul Dhorda; Phaik Yeong Cheah; Sasithon Pukrittayakamee; Elizabeth A Ashley; Tim J C Anderson; Shalini Nair; Marina McDew-White; Jennifer A Flegg; Eric P M Grist; Philippe Guerin; Richard J Maude; Frank Smithuis; Arjen M Dondorp; Nicholas P J Day; François Nosten; Nicholas J White; Charles J Woodrow Journal: Lancet Infect Dis Date: 2015-02-20 Impact factor: 25.071
Authors: Sreekanth Kokkonda; Xiaoyi Deng; Karen L White; Farah El Mazouni; John White; David M Shackleford; Kasiram Katneni; Francis C K Chiu; Helena Barker; Jenna McLaren; Elly Crighton; Gong Chen; Inigo Angulo-Barturen; Maria Belen Jimenez-Diaz; Santiago Ferrer; Leticia Huertas-Valentin; Maria Santos Martinez-Martinez; Maria Jose Lafuente-Monasterio; Rajesh Chittimalla; Shatrughan P Shahi; Sergio Wittlin; David Waterson; Jeremy N Burrows; Dave Matthews; Diana Tomchick; Pradipsinh K Rathod; Michael J Palmer; Susan A Charman; Margaret A Phillips Journal: J Med Chem Date: 2020-04-16 Impact factor: 7.446
Authors: Michael J Palmer; Xiaoyi Deng; Shawn Watts; Goran Krilov; Aleksey Gerasyuto; Sreekanth Kokkonda; Farah El Mazouni; John White; Karen L White; Josefine Striepen; Jade Bath; Kyra A Schindler; Tomas Yeo; David M Shackleford; Sachel Mok; Ioanna Deni; Aloysus Lawong; Ann Huang; Gong Chen; Wen Wang; Jaya Jayaseelan; Kasiram Katneni; Rahul Patil; Jessica Saunders; Shatrughan P Shahi; Rajesh Chittimalla; Iñigo Angulo-Barturen; María Belén Jiménez-Díaz; Sergio Wittlin; Patrick K Tumwebaze; Philip J Rosenthal; Roland A Cooper; Anna Caroline Campos Aguiar; Rafael V C Guido; Dhelio B Pereira; Nimisha Mittal; Elizabeth A Winzeler; Diana R Tomchick; Benoît Laleu; Jeremy N Burrows; Pradipsinh K Rathod; David A Fidock; Susan A Charman; Margaret A Phillips Journal: J Med Chem Date: 2021-04-20 Impact factor: 7.446
Authors: James G Kublin; Sean C Murphy; Janine Maenza; Annette M Seilie; Jay Prakash Jain; David Berger; Danielle Spera; Rong Zhao; Rachel L Soon; Julie L Czartoski; Meredith A Potochnic; Elizabeth Duke; Ming Chang; Ashley Vaughan; Stefan H I Kappe; F Joel Leong; Peter Pertel; William T Prince Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 9.079
Authors: John White; Satish K Dhingra; Xiaoyi Deng; Farah El Mazouni; Marcus C S Lee; Gustavo A Afanador; Aloysus Lawong; Diana R Tomchick; Caroline L Ng; Jade Bath; Pradipsinh K Rathod; David A Fidock; Margaret A Phillips Journal: ACS Infect Dis Date: 2018-11-13 Impact factor: 5.084